Sudarshan Pharma Share Price Today Jumps 9% After NSE Main Board Listing; Q2 Result, Fundraising Proposal Soon

Sudarshan Pharma Industries shares rallied nearly 9% on Wednesday, October 28, after the pharmaceutical company's equity shares transitioned from BSE's SME platform to the main board of the National Stock Exchange (NSE). The development brought the small-cap pharma stock into focus ahead of a key board meeting scheduled for Thursday, when the company will consider its September-quarter earnings and a fund-raising proposal.

Sudarshan Pharma Share Price Today

The stock closed at Rs 38.00, gaining Rs 3.12 or 8.94% during the session. It opened at Rs 36.99 and traded between an intraday low of Rs 34.46 and a high of Rs 38.00, according to the available market data.

The immediate development drawing investor attention was the migration of Sudarshan Pharma's equity shares to the NSE main board. In an exchange filing, the company said its shares would be listed and admitted to trading on the NSE Capital Market Segment with effect from October 27, 2026, following the move from BSE's SME platform.

A transition from an SME platform to a main board segment can improve a company's visibility among market participants and make its shares easier to track across trading platforms. Such moves may also broaden investor participation, although the actual impact depends on trading activity, liquidity and market interest.

Sudarshan Pharma Q2 Results in October: Check Earnings Call Date

Sudarshan Pharma's board of directors is scheduled to meet on Thursday, October 29, 2026, to consider and approve the company's financial results for the second quarter of the financial year 2026-27 (Q2 FY27), covering the quarter ended September 30, 2026.

The board will also consider a proposal for raising funds, according to the information provided by the company. The details of any proposed fund-raising exercise, including its size, structure and intended use, will be important for investors to assess if the proposal is approved and formally announced.

The proposed fund-raising decision will be another key point to watch. While raising capital can support business expansion or other corporate requirements, the implications for existing shareholders depend on the method, terms and purpose of the proposed issue. Investors should therefore wait for the company's official announcement before drawing conclusions about its potential impact.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.